Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Eight herpesvirus infections in man
3. Common diseases caused by alphaherpesvirus
4. Common diseases caused by HSV
5. Common diseases caused by VZV
6. Herpes infections in immunocompromised hosts
7. Herpesvirus - latency and reactivation
8. Herpesvirus - infection, latency and reactivation
9. Electron micrograph of HSV particle
10. Morphology of herpesvirus virion
11. Productive replication cycle of herpesvirus
12. The herpesvirus genome
13. HSV and VZV antiviral therapy
14. Efficacy of antiviral agents for HSV
15. Nucleoside analogue therapy
16. Nucleoside analogues in historical prospective
17. Current herpes antivirals
18. Genes coding for proteins targeted by antivirals
19. Antiviral compounds inhibitors of DNA synthesis
20. Nucleoside analogues are not fully effective in vivo
21. Antiviral treatment fails to prevent recurrence
22. A new target - HSV helicase-primase complex
23. Genes coding for proteins targeted by antivirals (2)
24. HSV DNA replication inhibitors site of action
25. Helicase primase inhibitors (HPI)
26. Three highly active helicase-primase inhibitors
27. Clinical potential of HPIs
28. Antiviral activity: HPI compared with nucleoside
29. Studying HPI in vivo
30. Progress of lesions following neck inoculation
31. Neck skin and ear pinna sensory nerves
32. The cranial nerve roots and ganglia
33. Zosteriform infection model parameters
34. Parameters for assessing antiviral efficacy
35. BAY 57-1293 vs. famciclovir
36. BAY 57-1293 vs. famciclovir - weight change
37. BAY 57-1293 vs. famciclovir - survival
38. BAY 57-1293 vs. famciclovir - ear swelling
39. BAY 57-1293 vs. famciclovir - virus growth in skin
40. BAY 57-1293 vs. famciclovir - virus growth in ear
41. BAY 57-1293 vs. famciclovir - virus growth in CNS
42. BAY 57-1293 vs. famciclovir - conclusions
43. The effective dose of BAY 57-1293
44. Dose response to BAY 57-1293
45. BAY 57-1293 effective dose - conclusions
46. Effects of BAY 57-1293 on HSV-1
47. Effects of BAY 57-1293 on HSV-1: weight change
48. Effects of BAY 57-1293 on HSV-1: virus titres
49. HPIs are effective in vivo
50. The effects of HPI on HSV latency
51. The development of HPI antiviral drug resistance
52. Sensitivity of HSV clinical isolates to BAY 57-1293
53. Sensitivity of clinical isolates to HPI - conclusions
54. Selection of HPI resistant mutants
55. HSV-1 strains for study
56. Isolation of HPI resistant mutants
57. HPI resistant mutants
58. HPI resistant mutants - cross resistancy
59. HPI resistant mutants - sensitivity to nucleoside
60. HPI resistance mutants - DNA sequencing
61. Conserved helicase motifs
62. BAY 57-1293 resistant mutations in UL5 (1)
63. BAY-57-1293 resistant mutations in UL5 (2)
64. BAY-57-1293 resistant mutations in UL5 (3)
65. Predicted binding of BAY 57-1293 to helicase
66. BAY 57-1293 resistance originated in UL52
67. HSV UL52 (primase) protein
68. Mutant growth and pathogenicity
69. BAY r1/BAY r2 growth in tissue culture
70. UL5 protein: schematic representation
71. BAY 57 resistance mutations characteristics
72. Drug resistance in clinical practice
73. Will antiviral drug-resistance be a problem for HPI?
74. HPI resistance selection claimed so far
75. HPI resistance selection - dynamics
76. HPI resistance selection - clinical isolates
77. General conclusions of HPI resistance
78. The good news
79. Acknowledgements

Topics Covered

• Herpesvirus infections in man
• Diseases caused by alphaherpesvirus, HSV and VZV
• Immunocompromised hosts
• Infection, latency and reactivation
• Morphology of herpesvirus virion
• Productive replication cycle
• The herpesvirus genome
• HSV and VZV antiviral therapy
• Nucleoside analogue therapy
• Historical prospective
• Genes coding for proteins targeted by antivirals
• Inhibitors of DNA synthesis
• A new target
• HSV helicase-primase complex
• Clinical potential of Helicase primase inhibitors (HPIs)
• Studying HPI in vivo
• Antiviral efficacy
• Dose response
• The effects of HPI on HSV latency
• The development of HPI antiviral drug resistance
• HPI resistant mutants growth and pathogenicity

Links

Series:

• Antivirals

Categories:

• Clinical Practice
• Microbiology
• Pharmaceutical Sciences

Therapeutic Areas:

• Infectious Diseases

Talk Citation

Field, H.J. (2011, August 30). Herpes simplex virus and varicella-zoster virus helicase-primase inhibitors [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved November 21, 2024, from https://doi.org/10.69645/EJUO5115.
Export Citation (RIS)

Publication History

• Published on August 30, 2011

Financial Disclosures

• Dr. Hugh J. Field has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.